MBL77 - AN OVERVIEW

Therapy for relapsed/refractory disease needs to be determined dependant upon prior therapy and also The main reason why the first treatment method was no longer ideal (e.g., refractoriness vs. intolerance). Ibrutinib is The existing gold common therapy for clients with relapsed/refractory disorder, determined by the outcome of a number of stage I-